Oral anticoagulant therapies: Balancing the risks

American Journal of Health-System Pharmacy

Volumn 70, Issue 10 SUPPL.1, 2013, Pages

  Nutescu, Edith A ^a,b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS HOSPITAL AND HEALTH SCIENCES SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9; DABIGATRAN; EDOXABAN; PROTHROMBIN; RIVAROXABAN; WARFARIN;

ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD CLOTTING PARAMETERS; BLOOD CLOTTING TIME; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; DEEP VEIN THROMBOSIS; DRUG ACCUMULATION; DRUG APPROVAL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MONITORING; DRUG SAFETY; DRUG TARGETING; ECARIN CLOTTING TIME; ELECTIVE SURGERY; EMBOLISM; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; KIDNEY CLEARANCE; KIDNEY FUNCTION; LUNG EMBOLISM; MECHANICAL HEART VALVE; PRIORITY JOURNAL; PROTHROMBIN TIME; RISK ASSESSMENT; RISK MANAGEMENT; RISK REDUCTION; THROMBIN TIME; VENOUS THROMBOEMBOLISM;

EID: 84878334183     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp130040     Document Type: Article

References (37)

1. Neel S. Essential warfarin knowledge. In: Gulseth M, ed. Managing anticoagulation patients in the hospital. Bethesda, MD: American Society of Health-System Pharmacists; 2007:133-75.
2. Budnitz DS, Lovegrove MC, Shehab N et al. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011; 365:2002-12.
3. Coumadin (warfarin sodium) prescribing information. Princeton, NJ: Bristol-Myers Squibb Company; 2011 Oct. http://packageinserts.bms.com/pi/ pi-coumadin.pdf (accessed 2013 Jan 4).
4. Wittkowsky AK. Warfarin (AHFS 20:12.04). In: Murphy JE, ed. Clinical pharmacokinetics, 5th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2012:351-72. www.ashp.org/DocLibrary/Bookstore/P2548/Sample- Chapter-24.aspx (accessed 2013 Jan 4).
5. Eckhoff CD, DiDomenico RJ, Shapiro NL. Initiating warfarin therapy: 5 mg versus 10 mg. Ann Pharmacother. 2004; 38:2115-21. (Pubitemid 40169384)
6. Miyares MA, Davis K. Newer oral anticoagulants: a review of laboratory monitoring options and reversal agents in the hemorrhagic patient. Am J Health-Syst Pharm. 2012; 69:1473-84.
7. Hylek EM, Regan S, Go AS et al. Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin. Ann Intern Med. 2001; 135:393-400. (Pubitemid 32845864)
8. Pradaxa (dabigatran etexilate mesylate) prescribing information. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2012 May. www.pradaxa.com/pradaxa-prescribing-information.jsp (accessed 2013 Jan 4).
9. Xarel to (rivaroxaban) prescribing information. Titusville, NJ: Janssen Pharmaceuticals, Inc; 2012 Nov. www.xareltohcp.com/sites/default/files/pdf/ xarelto-0.pdf#zoom=100 (accessed 2013 Jan 4).
10. UPDATE 1-Bayer, J&J's Xarelto gets FDA priority review. July 9, 2012. http:// in.reuters.com/article/2012/07/09/bayer-xarelto-review- idINL3E8I939A20120709 (accessed 2013 Jan 4).
11. Eliquis (apixaban) prescribing information. Princeton, NJ: Bristol-Myers Squibb Company. 2012 Dec. http://packageinserts.bms.com/pi/pi-eliquis.pdf (accessed 2013 Jan 4).
12. Weitz JI, Connolly SJ, Patel I et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost. 2010; 104:633-41.
13. Raskob G, Cohen AT, Eriksson BI et al. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study. Thromb Haemost. 2010; 104:642-9.
14. Camm AJ, Bounameaux H. Edoxaban: a new oral direct factor Xa inhibitor. Drugs. 2011; 71:1503-26.
15. Kaatz S, Kouides PA, Garcia DA et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol. 2012; 87(Suppl 1):S141-5.
16. Wittkowsky AK. Novel oral anticoagulants and their role in clinical practice. Pharmacotherapy. 2011; 31:1175-91.
17. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361:1139-51.
18. Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365:883-91.
19. Granger CB, Alexander JH, McMurray JJ et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365:981-92.
20. Institute for Safe Medication Practices. QuarterWatch. Monitoring FDA Med- Watch reports: anticoagulants the leading reported drug risk in 2011. May 31, 2012. www.ismp.org/QuarterWatch/pdfs/2011Q4.pdf (accessed 2013 Jan 4).
21. Gage BF, Waterman AD, Shannon W et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001; 285:2864-70. (Pubitemid 32537350)
22. Lip GY, Nieuwlaat R, Pisters R et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest. 2010; 137:263-72.
23. You JJ, Singer DE, Howard PA et al. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012; 141(Suppl 2):e531S-75S.
24. Wann SL, Curtis AB, Ellenbogen KA et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011; 123:1144-50.
25. Fuster V, Rydén LE, Cannom DS et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2011; 123:e269-367.
26. Camm AJ, Lip GY, De Caterina R et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Eur Heart J. [Epub ahead of print] 2012 Aug 24. www.escardio.org/guidelines-surveys/esc-guidelines/ GuidelinesDocuments/Guidelines-Focused-Update-Atrial-Fib-FT.pdf (accessed 2013 Jan 4).
27. Gage BF, Yan Y, Milligan PE et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006; 151:713-9. (Pubitemid 43290267)
28. Pisters R, Lane DA, Nieuwlaat R et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010; 138:1093-100.
29. Lip GY, Frison L, Halperin JL et al. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol. 2011; 57:173-80.
30. Fang MC, Go AS, Chang Y et al. A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study. J Am Coll Cardiol. 2011; 58:395-401.
31. Douketis JD, Spyropoulos AC, Spencer FA et al. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012; 141(Suppl 2):e326S-50S.
32. Douketis JD, Johnson JA, Turpie AG. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen. Arch Intern Med. 2004; 164:1319-26. (Pubitemid 38828883)
33. Spyropoulos AC, Turpie AG, Dunn AS et al. Clinical outcomes with unfractionated heparin or low-molecular-weight heparin as bridging therapy in patients on long-term oral anticoagulants: the REGIMEN registry. J Thromb Haemost. 2006; 4:1246-52.
34. Viles-Gonzalez JF, Fuster V, Halperin JL. New anticoagulants for prevention of stroke in patients with atrial fibrillation. J Cardiovasc Electrophysiol. 2011; 22:948-55.
35. Schulman S, Crowther M. How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. Blood. 2012; 119:3016-23.
36. Palladino M, Thomson L, Swift B et al. Implementing the new oral anticoagulants into the hospital formulary. Am J Hematol. 2012; 87(Suppl 1):S127-32.
37. Van Veen JJ, Smith J, Kitchen S et al. Normal prothrombin time in the presence of therapeutic levels of rivaroxaban. Br J Haematol. [Epub ahead of print] 2012 Dec 29.